Compare Novartis AG (NVS) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard International High Dividend Yield ETF — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Vanguard International High Dividend Yield ETF trades at $102.18 (market cap $22.80B). The key difference: Novartis AG is far larger — about 11.8× Vanguard International High Dividend Yield ETF's market cap, and Novartis AG pays a 3.31% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| NVS | VYMI | |
|---|---|---|
Market Cap | $268.57B | $22.80B |
Volume | 1,532,573 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $107.13 |
52-Week Low | $121.80 | $82.92 |
Typical Hold Time | 82 Days | 50 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
VYMI trades at $100.23, down 1.11% today amid bearish technical signals. The ETF shows strong institutional interest with multiple firms increasing holdings recently. Recent analysis highlights VYMI's 5-year average annual return of 14.13% and 3.61% dividend yield, outperforming peers despite current technical weakness.
The outlook remains positive given VYMI's exposure to international dividend stocks benefiting from higher global rates. Key risks include currency fluctuations and concentrated financial sector exposure. Analyst sentiment leans bullish with expectations of continued international stock outperformance versus US markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
